相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1868
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The District Court The Hague dismissed nullity suits from Accord Healthcare and Sandoz against Xtandi's basic patent EP 1 893 196 and its Dutch SPC, maintaining protection until June 2028. - Generic companies challenged the patent's priority claims, arguing the lead compound RD 162 was previously published, but the court rejected their arguments. - The ruling continues Astellas and University of California's successful European defense of Xtandi patents, following similar victories in the UK and Germany. - Appeals remain pending in the UK regarding the same patent, while Dutch appeals are expected as generic companies previously appealed a related formulation patent decision.
- The Delhi High Court upheld patent rejections in two separate pharmaceutical cases, reinforcing strict disclosure requirements and amendment limitations under Indian patent law. - In the University of California case, the court ruled that insufficient disclosure of recombinant Salmonella vaccine mutations violated mandatory requirements under Sections 10(4) and 10(5) of the Patents Act. - The AbbVie case established that converting method-of-treatment claims to broader product claims without disease-specific limitations constitutes impermissible scope enlargement under Section 59(1). - Both rulings emphasize that patent specifications must provide adequate working embodiments and that amendments cannot artificially broaden claims beyond original disclosure.
